Trial Profile
A Phase Ib/II Randomized Double-blind Placebo Controlled Trial Evaluating the Effect of Nivolumab for Patients With In-transit Melanoma Metastases Treated With Isolated Limb Perfusion - the NivoILP Trial
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 13 Apr 2024
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Melphalan; Tasonermin
- Indications Malignant melanoma
- Focus Therapeutic Use
- Acronyms NivoILP
- 20 Nov 2023 Planned End Date changed from 1 Dec 2025 to 1 Dec 2027.
- 20 Nov 2023 Planned primary completion date changed from 1 Dec 2023 to 1 Dec 2025.
- 03 May 2022 Planned End Date changed from 1 Dec 2023 to 1 Dec 2025.